Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 114, Issue 2, 2009, Pages 195-201

  Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Tubulin; Chemotherapy resistant; Drug efflux proteins; Ixabepilone; Metastatic breast cancer; P gp

Indexed keywords

9,10 DIDEHYDROEPOTHILONE D; ABJ 879; ALBUMIN; ANTHRACYCLINE DERIVATIVE; BETA TUBULIN; CAPECITABINE; CARBOPLATIN; CARMOFUR; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EPOTHILONE B; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; IXABEPILONE; LAROTAXEL; METHOTREXATE; MITOMYCIN; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; RPR 109881; TAXANE DERIVATIVE; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ALOPECIA; ARTHRALGIA; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CROSS RESISTANCE; DIARRHEA; DRUG DELIVERY SYSTEM; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; GENETIC MARKER; HAND FOOT SYNDROME; HUMAN; HYPERSENSITIVITY REACTION; METASTASIS; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSORY NEUROPATHY; VOMITING;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; FLUOROURACIL; HUMANS; TAXOIDS; TUBULIN MODULATORS;

EID: 59449102796     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0005-6     Document Type: Review

References (69)

1. Jemal A, Siegel R, Ward E et al (2008) Cancer Statistics, 2008. Available via CA Cancer J Clin. http://caoline.amcancersoc.org/cgi/content/full/CA.2007. 0010v1. Accessed 5 Mar 2008
2. Ries LAG, Melbert D, Krapcho M et al (eds) (2006) SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. http://seer.cancer.gov/csr/1975- 2004. Accessed 11 Feb 2008
3. C Bernard-Marty F Cardoso MJ Piccart 2004 Facts and controversies in systemic treatment of metastatic breast cancer Oncologist 9 617 632
4. CL Vogel MA Cobleigh D Tripathy 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 726
5. CE Geyer J Forster D Lindquist 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743
6. NCCN (2008) Breast cancer; clinical practice guidelines in oncology - v.2. http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf. Accessed 11 Feb 2008
7. A Hamilton G Hortobagyi 2005 Chemotherapy: what progress in the last 5 years? J Clin Oncol 23 1760 1775
8. Y Fujiwara 1999 Current status of oral anticancer drugs in Japan J Clin Oncol 17 3362 3365
9. SH Giordano AU Buzdar TL Smith SW Kau Y Yang GN Hortobagyi 2004 Is breast cancer survival improving? Cancer 100 44 52
10. J Bonneterre V Dieras M Tubiana-Hulin 2004 Phase II multicentre randomised study of docetaxel plus epirubicin vs. 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer Br J Cancer 91 1466 1471
11. 2 as first-line chemotherapy in patients with advanced or recurrent breast cancer Breast Cancer 11 374 379
12. M Vassilomanolakis G Koumakis V Barbounis 2005 First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer Breast 14 136 141
13. K Porkka C Blomqvist P Rissanen I Elomaa S Pyrhönen 1994 Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer J Clin Oncol 12 1639 1647
14. M Gottesman 2002 Mechanisms of cancer drug resistance Ann Rev Med 53 615 627
15. A Sparreboom R Danesi Y Ando J Chan WD Figg 2003 Pharmacogenomics of ABC transporters and its role in cancer chemotherapy Drug Resist Updat 6 71 84
16. P Borst R Evers M Kool J Wijnholds 2000 A family of drug transporters: the multidrug resistance-associated proteins J Natl Cancer Inst 92 1295 1302
17. GD Leonard T Fojo SE Bates 2003 The role of ABC transporters in clinical practice Oncologist 8 411 424
18. MM Gottesman T Fojo SE Bates 2002 Multidrug resistance in cancer: role of ATP-dependent transporters Nat Rev Cancer 2 48 58
19. YN Chen LA Mickley AM Schwartz EM Acton J Hwang AT Fojo 1990 Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein J Biol Chem 265 10073 10080
20. LA Doyle DD Ross 2003 Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) Oncogene 22 7340 7358
21. CH Yang E Schneider ML Kuo EL Volk E Rocchi YC Chen 2000 BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells Biochem Pharmacol 60 831 837
22. BJ Trock F Leonessa R Clarke 1997 Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance J Natl Cancer Inst 89 917 931
23. F Leonessa R Clarke 2003 ATP binding cassette transporters and drug resistance in breast cancer Endocr Relat Cancer 10 43 73
24. M Kavallaris 1997 The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance Anti-Cancer Drugs 8 17 25
25. Y Honjo CA Hrycyna QW Yan 2001 Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells Cancer Res 61 6635 6639
26. NM Verrills M Kavallaris 2005 Improving the targeting of tubulin-binding agents: lessons from drug resistance studies Curr Pharm Des 11 1719 1733
27. A Paradiso A Mangia A Chiriatti 2005 Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer Ann Oncol 16 suppl. 4 iv14 iv19
28. K Kamath L Wilson F Cabral MA Jordan 2005 ßIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability J Biol Chem 280 12902 12907
29. H Zhu W Guo L Zhang 2005 Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells Mol Cancer Ther 4 451 456
30. T Brooks H Minderman KL O'Loughlin 2003 Taxane-based reversal agents modulate drug resistance mediated by p-glycoprotein, multidrug resistance protein, and breast cancer resistance protein Mol Cancer Ther 2 1195 1205
31. H Thomas HM Coley 2003 Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein Cancer Control 10 159 165
32. M Menefee C Fan M Edgerly 2005 Tariquidar (XR9576) is a potent and effective p-glycoprotein (pgp) inhibitor that can be administered safely with chemotherapy J Clin Oncol 23 16S Abstract 3093
33. L Pusztai P Wagner N Ibrahim 2005 Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma Cancer 104 682 691
34. P Fumoleau R Largillier C Clippe 2004 Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer Eur J Cancer 40 536 542
35. Xeloda tablets [package insert] (2006) Nutley, NJ: Roche Pharmaceuticals
36. JL Blum SE Jones AU Buzdar 1999 Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer J Clin Oncol 17 485 493
37. JL Blum 2001 The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer Oncologist 6 56 64
38. JL Blum V Dieras PM Lo Russo 2001 Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 1759 1768
39. ®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy Ann Oncol 14 1227 1233
40. EA Wist HH Sommer B Stenstad T Risbert Y Bremnes I Mjaaland 2004 Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer Acta Oncol 43 186 189
41. T Petit A Benider A Yovine 2006 Phase II study of an oxaliplatin/ vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer Anticancer Drugs 17 337 343
42. L Zelek P Cottu M Tubiana-Hulin 2002 Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients J Clin Oncol 20 2551 2558
43. EA Perez 2004 Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes Clin Breast Cancer 4 S113 S116
44. PA Burch JA Mailliard DW Hillman 2005 Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group trial Am J Clin Oncol 28 195 200
45. JH Seo SC Oh CW Choi 2007 Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer Cancer Chemother Pharmacol 59 269 274
46. JL Blum MA Savin G Edelman 2004 Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel J Clin Oncol 22 14S Abstract 543
47. V Dieras V Valero S Limentani 2005 Multicenter, non-randomized phase II study with RPR109881 in taxane-exposed metastatic breast cancer (MBC) patients (pts): final results J Clin Oncol 23 16S Abstract 565
48. WJ Gradishar S Tjulandin N Davidson 2005 Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J Clin Oncol 23 7794 7803
49. Capecitabine and paclitaxel (albumin-stabilized nanoparticle formulation) in treating women undergoing surgery for stage II or stage III breast cancer. http://clinicaltrials.gov/ct2/show/NCT00397761. Accessed 8 Feb 2008
50. Chemotherapy, G-CSF, and ABI-007 with or without trastuzumab in treating women with high-risk localized breast cancer. http://clinicaltrials.gov/ct2/ show/NCT00407888. Accessed 8 Feb 2008
51. Paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, and gemcitabine as first-line therapy in treating patients with metastatic breast cancer. http://clinicaltrials.gov/ct2/show/NCT00503906. Accessed 8 Feb 2008
52. Combination study of a new taxane and capecitabine in patients with metastatic breast cancer. http://clinicaltrials.gov/ct2/show/NCT00327743. Accessed 8 Feb 2008
53. 2 or docetaxel every 3 weeks, alone or with trastuzumab according to Her2/neu status, after combination of anthracycline and cyclophosphamide as preoperative therapy in patients with high risk localized breast cancer. http://clinicaltrials.gov/ct2/show/NCT00485979. Accessed 3 Mar 2008
54. ® in patients with HER2 positive metastatic breast cancer. http://clinicaltrials. gov/ct2/show/NCT00387907. Accessed 8 Feb 2008
55. JA O'Shaughnessy RS Clark JL Blum 2005 Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer Clin Breast Cancer 6 143 149
56. S Vukelja J O'Shaughnessy S Campos 2005 Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: phase 2 study results J Clin Oncol 23 16S Abstract 562
57. EA Perez DW Hillman JA Mailliard 2004 Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both J Clin Oncol 22 2849 2855
58. EA Perez G Lerzo X Pivot 2007 Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine J Clin Oncol 25 3407 3414
59. FY Lee R Borzilleri CR Fairchild 2001 BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy Clin Cancer Res 7 1429 1437
60. DM Bollag PA McQueney J Zhu 1995 Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action Cancer Res 55 2325 2333
61. YW Chin MJ Balunas HB Chai AD Kinghorn 2006 Drug discovery from natural resources AAPS J 8 E239 E253
62. P Giannakakou R Gussio E Nogales 2000 A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells Proc Natl Acad Sci USA 97 2904 2909
63. P Giannakakou DL Sackett YK Kang 1997 Paclitaxel-resistant human ovarian cancer cells have mutant ß-tubulins that exhibit impaired paclitaxel-driven polymerization J Biol Chem 272 17118 17125
64. J Cortes J Baselga 2007 Targeting the microtubules in breast cancer beyond taxanes: the epothilones Oncologist 12 271 280
65. Zhou Y, Zhong Z, Liu F et al (2005) KOS-1584: a rationally designed epothilone D analog with improved potency and pharmacokinetic (PK) properties. Proc Amer Assoc Cancer Res 46: Abstract 2535
66. ® resistance recapitulates the phenotype of its origin has altered beta-tubulin expression and is sensitive to ixabepilone. The 97th AACR Annual Meeting, Washington DC, April 1-5, 2006 Abstract LB-280
67. E Thomas J Tabernero M Fornier 2007 Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer J Clin Oncol 25 3399 3406
68. V Valero SE Jones DD Von Hoff 1998 A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer J Clin Oncol 16 3362 3368
69. ES Thomas HL Gomez RK Li 2007 Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 5210 5217